

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

**COMPLETION OF DISCLOSEABLE AND CONNECTED TRANSACTION
IN RELATION TO THE ACQUISITION OF
REMAINING 40% EQUITY INTEREST
IN TONGFANG PHARMACEUTICAL
INVOLVING THE ISSUE OF
CONSIDERATION SHARES UNDER SPECIFIC MANDATE**

References are made to the announcements respectively dated 23 January 2018 and 16 March 2018 and the circular dated 27 February 2018 (the “**Circular**”) of Tongfang Kontafarma Holdings Limited (the “**Company**”), in relation to the acquisition of remaining 40% equity interest in 同方藥業集團有限公司 (Tongfang Pharmaceutical Group Co., Ltd*) (“**Tongfang Pharmaceutical**”) (the “**Acquisition**”) involving the issue of Consideration Shares under Specific Mandate which constituted discloseable and connected transaction of the Company. Capitalised terms used in this announcement have the same meanings as defined in the Circular unless otherwise defined.

The Board is pleased to announce that all the conditions precedent for the Acquisition had been fulfilled and the completion of the Acquisition contemplated under the Sale and Purchase Agreement took place on 3 May 2018 in accordance with the terms and conditions as set out therein. Upon the completion, Tongfang Pharmaceutical became an indirect wholly-owned subsidiary of the Company.

By Order of the Board
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 3 May 2018

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Huang Yu (Chairman), Mr. Jiang Chaowen (Chief Executive Officer) and Mr. Ng Qing Hai; and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.

* *for identification purpose only*